Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C N Graham

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Effect Of Sample Size And Data Maturity On Parametric Survival Modeling Projections In Advanced CancerC N Graham, K L Davis, R K Goyal
Journal of the European Academy of Dermatology and Venereology : JEADV|May 6, 2018
Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in GermanyM Augustin, D McBride, I Gilloteau, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2018
Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United KingdomR B Warren, A Halliday, C N Graham, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 18, 2015
Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatmentS R Earnshaw, C N Graham, C L McDade, et al.
Current Medical Research and Opinion|September 11, 2007
Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonatesS R Earnshaw, C N Graham, B Ettinger, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Cost-Effectiveness Analysis of Panitumumab Plus Mfolfox6 Versus Bevacizumab Plus Mfolfox6 for First-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal CancerC N Graham, G Hechmati, J Hjelmgren, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Effect Of Sample Size And Data Maturity On Parametric Survival Modeling Projections In Advanced CancerC N Graham, K L Davis, R K Goyal
Journal of the European Academy of Dermatology and Venereology : JEADV|May 6, 2018
Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in GermanyM Augustin, D McBride, I Gilloteau, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 31, 2018
Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United KingdomR B Warren, A Halliday, C N Graham, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 18, 2015
Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatmentS R Earnshaw, C N Graham, C L McDade, et al.
Current Medical Research and Opinion|September 11, 2007
Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonatesS R Earnshaw, C N Graham, B Ettinger, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Cost-Effectiveness Analysis of Panitumumab Plus Mfolfox6 Versus Bevacizumab Plus Mfolfox6 for First-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal CancerC N Graham, G Hechmati, J Hjelmgren, et al.
Pageof 1